← All companies

PLYX

Polaryx Therapeutics, Inc.

PLYX Nasdaq Pharmaceutical Preparations EDGAR ↗

$2.19

+0.04 +1.86%

Key statistics

from XBRL data in SEC filings

Market cap

$104M

Revenue (TTM)

—

Net income (TTM)

-$8.98M

EPS (TTM)

$-0.20

P/E ratio

—

Dividend yield

—

Free cash flow

—

Cash

$3.08M

Total assets

$3.50M

Gross margin

—

52-week range

$1.86 – $48.91

Recent SEC filings

32 most recent

Annual, quarterly & current reports

8-K Director or officer change Jul 21, 2026 8-K Item 5.08; Other events Jul 17, 2026 8-K Entered a material agreement; Unregistered sale of equity; Regulation FD disclosure May 28, 2026 10-Q Quarter ended 2026-03-31 May 15, 2026 10-K Fiscal year ended 2025-12-31 Mar 24, 2026

Other filings

ARS Jul 28, 2026 DEFA14A DEFINITIVE ADDITIONAL MATERIALS Jul 28, 2026 DEF 14A PROXY STATEMENT Jul 28, 2026 S-8 REGISTRATION STATEMENT Jul 24, 2026 4 May 28, 2026 4 Feb 20, 2026 SCHEDULE 13D Feb 5, 2026 424B4 PROSPECTUS Feb 2, 2026 EFFECT Jan 29, 2026 3 OWNERSHIP DOCUMENT Jan 29, 2026 3 OWNERSHIP DOCUMENT Jan 29, 2026 3 OWNERSHIP DOCUMENT Jan 29, 2026 3 OWNERSHIP DOCUMENT Jan 29, 2026 3 OWNERSHIP DOCUMENT Jan 29, 2026 3 OWNERSHIP DOCUMENT Jan 29, 2026 3 OWNERSHIP DOCUMENT Jan 29, 2026 CERT Jan 28, 2026 8-A12B FOR REGISTRATION OF CERTAIN CLASSES Jan 27, 2026 S-1/A REGISTRATION STATEMENT Jan 27, 2026 S-1/A REGISTRATION STATEMENT Jan 14, 2026 S-1 REGISTRATION STATEMENT Nov 21, 2025 C-U Oct 31, 2025 C-U Oct 27, 2025 C/A Oct 1, 2025 DRS/A Sep 19, 2025 C Sep 3, 2025 DRS Aug 5, 2025